Criteria and definitions for the radiological and clinical diagnosis of bronchiectasis in adults for use in clinical trials: international consensus recommendations.

[1]  O. Sibila,et al.  A CLUSTER ANALYSIS OF BRONCHIECTASIS PATIENTS BASED ON THE AIRWAY IMMUNE PROFILE. , 2020, Chest.

[2]  H. Goossens,et al.  Efficacy and safety of TOBI Podhaler in Pseudomonas aeruginosa-infected bronchiectasis patients: iBEST study , 2020, European Respiratory Journal.

[3]  H. Tiddens,et al.  Diagnosis and quantification of bronchiectasis using computed tomography or magnetic resonance imaging: A systematic review. , 2020, Respiratory medicine.

[4]  F. Lapi,et al.  Prevalence and incidence of bronchiectasis in Italy , 2020, BMC Pulmonary Medicine.

[5]  T. Welte,et al.  Increasing bronchiectasis prevalence in Germany, 2009–2017: a population-based cohort study , 2019, European Respiratory Journal.

[6]  S. Salvi,et al.  Bronchiectasis in India: results from the European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC) and Respiratory Research Network of India Registry. , 2019, The Lancet. Global health.

[7]  M. Surette,et al.  A longitudinal characterization of the Non-Cystic Fibrosis Bronchiectasis airway microbiome , 2019, Scientific Reports.

[8]  J. Chalmers,et al.  A systematic review of pharmacotherapeutic clinical trial end-points for bronchiectasis in adults , 2019, European Respiratory Review.

[9]  Meilan K. Han,et al.  Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019 , 2019, European Respiratory Journal.

[10]  A. O'donnell,et al.  Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with Pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials. , 2019, The Lancet. Respiratory medicine.

[11]  R. Diel,et al.  The economic burden of bronchiectasis – known and unknown: a systematic review , 2019, BMC Pulmonary Medicine.

[12]  L. Dupont,et al.  National Survey on the Management of Adult Bronchiectasis in Belgium , 2019, COPD.

[13]  A. Agustí,et al.  Clinical Fingerprinting: A Way to Address the Complexity and Heterogeneity of Bronchiectasis in Practice. , 2019, American journal of respiratory and critical care medicine.

[14]  K. Rabe,et al.  Economic burden of bronchiectasis in Germany , 2018, European Respiratory Journal.

[15]  M. Tunney,et al.  British Thoracic Society Guideline for bronchiectasis in adults , 2018, Thorax.

[16]  C. Daley,et al.  Characteristics and Health‐care Utilization History of Patients With Bronchiectasis in US Medicare Enrollees With Prescription Drug Plans, 2006 to 2014 , 2018, Chest.

[17]  P. Flume,et al.  Advances in bronchiectasis: endotyping, genetics, microbiome, and disease heterogeneity , 2018, The Lancet.

[18]  M. Miravitlles,et al.  The overlap between bronchiectasis and chronic airway diseases: state of the art and future directions , 2018, European Respiratory Journal.

[19]  Christoph Gerlinger,et al.  Characterization of the “Frequent Exacerbator Phenotype” in Bronchiectasis , 2018, American journal of respiratory and critical care medicine.

[20]  D. Obradović,et al.  The independent contribution of Pseudomonas aeruginosa infection to long-term clinical outcomes in bronchiectasis , 2018, European Respiratory Journal.

[21]  J. Elborn,et al.  RESPIRE 2: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis , 2018, European Respiratory Journal.

[22]  Katrin Roth,et al.  RESPIRE 1: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis , 2018, European Respiratory Journal.

[23]  D. Obradović,et al.  Standardised classification of the aetiology of bronchiectasis using an objective algorithm , 2017, European Respiratory Journal.

[24]  T. Welte,et al.  European Respiratory Society guidelines for the management of adult bronchiectasis , 2017, European Respiratory Journal.

[25]  F. Blasi,et al.  The European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC): experiences from a successful ERS Clinical Research Collaboration , 2017, Breathe.

[26]  T. Welte,et al.  Pulmonary exacerbation in adults with bronchiectasis: a consensus definition for clinical research , 2017, European Respiratory Journal.

[27]  Raúl San José Estépar,et al.  Quantitative CT Measures of Bronchiectasis in Smokers , 2017, Chest.

[28]  J. Chalmers,et al.  Investigating the Etiology of Bronchiectasis: You Do Not Find What You Do Not Look For , 2017, Respiration.

[29]  M. Mantero,et al.  Quality standards for the management of bronchiectasis in Italy: a national audit , 2016, European Respiratory Journal.

[30]  A. Torres,et al.  Etiology of Non-Cystic Fibrosis Bronchiectasis in Adults and Its Correlation to Disease Severity. , 2015, Annals of the American Thoracic Society.

[31]  J. M. Salge,et al.  Aging of the Lungs in Asymptomatic Lifelong Nonsmokers: Findings on HRCT , 2015, Lung.

[32]  N. Müller,et al.  Fleischner Society: glossary of terms for thoracic imaging. , 2008, Radiology.

[33]  M. Denton,et al.  Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients. , 2003, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[34]  Hideki Shima,et al.  Bronchoarterial ratio and bronchial wall thickness on high-resolution CT in asymptomatic subjects: correlation with age and smoking. , 2003, AJR. American journal of roentgenology.